26th Sep 2018 07:00
Silence Therapeutics to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
September 26 2018
LONDON, Silence Therapeutics plc, (AIM:SLN) ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces that David Horn Solomon, Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Wednesday, October 3, 2018 at 12:15pm EDT in New York, NY.
The presentation will be webcast live and may be accessed by visiting Silence's website at https://www.silence-therapeutics.com/news-media/events/. A replay of the webcast will be available for 14 working days.
Enquiries:
| Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer Dr Andy Richards, CBE, Interim Chair David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
|
|
|
| Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
| European IR Consilium Strategic Communications Mary-Jane Elliot / Angela Gray
| Tel: +44 (0) 20 3709 5700 |
| US IR Burns McClellan Lisa Burns, Jill Steier, John Grimaldi
| Tel: +1 (212) 213-0006 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
Related Shares:
SLN.L